TaiGen Biotechnology Company, Limited (TaiGen) announces that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of all influenza symptoms after treatment with TG-1000 was significantly shorter compared to the placebo group. Furthermore, TG-1000 demonstrated a favourable safety profile, with no clinically significant safety concerns observed.
Taiwan's TaiGen Biotechnology has signed an exclusive licensing agreement with Joincare Pharmaceutical Group, a Chinese pharmaceutical company, to develop and commercialise TG-1000 in China.